Key result
Levosimendan administration significantly preserved muscle viability (60.7% vs 36.6%, p<0.001) and improved kidney microcirculation compared to vehicle in a rat model of lower limb ischemia-reperfusion.
Why the study?
Does levosimendan prevent lower limb ischemia-reperfusion injury and corollary renal dysfunction in a rat model of bilateral lower limb ischemia?
Population
44 Male Wistar rats weighing 200-250 grams undergoing 180 min bilateral lower limb ischemia followed by 4 or…
Comparison
Intravenous levosimendan throughout 180 min… vs Ischemia-reperfusion and sham-operated groups…
Design
Preclinical, distributed randomly into two main groups defined by the proposed…
Follow-up
4 or 24 hours of reperfusion
Authors
Loading...
Hypothesis-generating for levosimendan in limb ischemia-reperfusion; clinical trials required before translation.
Does levosimendan prevent lower limb ischemia-reperfusion injury and corollary renal dysfunction in a rat model of bilateral lower limb ischemia?
Absolute Event Rate: 60.746% vs 36.601%
p-value: p=<0.001
In a rat model of lower limb ischemia, levosimendan administration preserved muscle viability and attenuated secondary acute kidney injury, suggesting a potential protective role during major vascular surgeries.
Ónody et al. (2016) studied Lower limb ischemia-reperfusion injury and acute renal failure (n=44). Levosimendan vs. Vehicle (5g/100ml glucose solution) was evaluated on Muscle viability at 4 hours (p=<0.001). Levosimendan administration significantly preserved muscle viability (60.7% vs 36.6%, p<0.001) and improved kidney microcirculation compared to vehicle in a rat model of lower limb ischemia-reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: